Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 38.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,155 shares of the biopharmaceutical company's stock after selling 5,162 shares during the period. Nisa Investment Advisors LLC's holdings in Alnylam Pharmaceuticals were worth $2,202,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Banque Pictet & Cie SA acquired a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $400,000. Crossmark Global Holdings Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $275,000. Envestnet Asset Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 9.1% in the first quarter. Envestnet Asset Management Inc. now owns 72,047 shares of the biopharmaceutical company's stock valued at $19,454,000 after buying an additional 6,033 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Alnylam Pharmaceuticals by 10,066.7% in the first quarter. Penserra Capital Management LLC now owns 1,220 shares of the biopharmaceutical company's stock valued at $329,000 after buying an additional 1,208 shares during the last quarter. Finally, IFM Investors Pty Ltd raised its position in shares of Alnylam Pharmaceuticals by 9.4% in the first quarter. IFM Investors Pty Ltd now owns 25,919 shares of the biopharmaceutical company's stock valued at $7,129,000 after buying an additional 2,219 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Scotiabank upped their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. Stifel Nicolaus upped their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. HC Wainwright reaffirmed a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. BMO Capital Markets upped their price target on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 24th. Finally, JPMorgan Chase & Co. upped their price target on shares of Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the stock an "overweight" rating in a research report on Thursday, June 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-two have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $345.70.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at approximately $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Stock Down 1.5%

ALNY traded down $4.63 during trading on Tuesday, hitting $311.12. The company had a trading volume of 927,235 shares, compared to its average volume of 855,049. The company has a market cap of $40.57 billion, a PE ratio of -148.86 and a beta of 0.23. The business has a 50-day moving average of $302.84 and a 200-day moving average of $269.96. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $333.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm's revenue for the quarter was up 20.2% on a year-over-year basis. During the same period last year, the company posted ($0.16) earnings per share. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.